TuHURA Biosciences, Inc.(HURA) - 2025 Q3 - Quarterly Results

Form 8-K: Current Report This Form 8-K details company and filing information, recent financial results, a proposed merger, cautionary statements, and relevant exhibits Company and Filing Details This Form 8-K was filed by TuHURA Biosciences, Inc. on May 15, 2025, with its common stock registered on The Nasdaq Capital Market under the symbol HURA - Filing entity: TuHURA BIOSCIENCES, INC., a Nevada corporation[2] - Report date: May 15, 2025[2] Registered Securities | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | :--- | :--- | :--- | | Common Stock, $0.001 par value per share | HURA | The Nasdaq Capital Market | Item 2.02 Results of Operations and Financial Condition On May 15, 2025, TuHURA Biosciences issued a press release (Exhibit 99.1) announcing its financial results for the three months ended March 31, 2025, and providing a corporate update, with the information considered furnished, not filed - A press release was issued on May 15, 2025, detailing financial results for the quarter ended March 31, 2025[7] - Exhibit 99.1, the press release, includes a corporate update[7] - Information in this report and exhibit is furnished, not filed, under the Securities Exchange Act of 1934, unless explicitly referenced in future filings[7] Proposed Merger with Kineta, Inc. This section details the proposed merger with Kineta, Inc., referencing the Form S-4 registration statement filed with the SEC, clarifying that this 8-K is not a solicitation and identifying participants Important Additional Information TuHURA filed a Form S-4 registration statement on February 7, 2025, containing a preliminary joint proxy statement and prospectus regarding the proposed merger with Kineta, which will be available on the SEC and TuHURA websites - TuHURA filed a Form S-4 registration statement with the SEC on February 7, 2025, regarding the proposed merger with Kineta, Inc[8] - Investors are urged to review the Joint Proxy Statement/Prospectus for critical merger information[8] - Finalized documents will be mailed to stockholders and accessible on the SEC's website (www.sec.gov) and TuHURA's website (www.tuhurabio.com)[9](index=9&type=chunk) No Offer or Solicitation This Form 8-K is explicitly not a proxy statement, an offer to sell, or a solicitation of an offer to buy any securities in relation to the merger, with any securities offering to be conducted via a prospectus - This Form 8-K is not a proxy statement or a solicitation for the merger[10] - It does not constitute an offer to sell or a solicitation to buy securities of TuHURA or Kineta[10] Participants in the Solicitation The directors and executive officers of both TuHURA and Kineta may be considered participants in the solicitation of proxies for the merger, with details regarding their interests disclosed in SEC filings and the Joint Proxy Statement/Prospectus - Directors and officers of TuHURA and Kineta may be considered participants in the merger's proxy solicitation[11] - Information on TuHURA's directors and officers is available in its Form 10-K filed on March 31, 2025[11] - Further details on participant interests will be provided in the Joint Proxy Statement/Prospectus[11][12] Cautionary Statement Regarding Forward-Looking Statements This report contains forward-looking statements concerning TuHURA's product candidates, development programs, the proposed merger with Kineta, and capital requirements, which are based on current expectations and not guarantees of future performance, with no obligation to update them - Forward-looking statements cover TuHURA's IFx-Hu2.0 product candidate, tumor microenvironment modulators program, and the potential acquisition of Kineta Inc[13] - Statements also address capital resources, additional capital needs (including for the Kineta merger), and regulatory pathways[13] - The company disclaims any obligation to publicly update or revise forward-looking statements unless legally mandated[14] Item 9.01 Financial Statements and Exhibits This section lists the exhibits filed with the Form 8-K, primarily the press release from May 15, 2025, containing financial results and a corporate update Exhibits | Exhibit No. | Document Description | | :--- | :--- | | 99.1 | Press Release, dated May 15, 2025 | | 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | Signatures The report was officially signed on May 15, 2025, by Dan Dearborn, the Chief Financial Officer of TuHURA Biosciences, Inc - The report is signed by Dan Dearborn, Chief Financial Officer[21] - Signature date: May 15, 2025[21]